DFV890

DRUG8 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Atherosclerotic cardiovascular diseaseCOVID-19 Pneumonia, Impaired Respiratory FunctionClonal Hematopoiesis of Indeterminate Potential (CHIP)Coronary Heart DiseaseFamilial Cold Autoinflammatory SyndromeKnee OsteoarthritisMyeloid DiseasesSymptomatic Knee Osteoarthritis

Phase 1

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Active, not recruitingNCT05552469

Novartis PharmaceuticalsMyeloid Diseases

Start: 2023-05-08End: 2027-01-13Updated: 2026-03-27

Phase 2

Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia

CompletedNCT04382053

Novartis PharmaceuticalsCOVID-19 Pneumonia, Impaired Respiratory Function

Start: 2020-05-27End: 2020-12-24Updated: 2022-07-26

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

CompletedNCT04868968

Novartis PharmaceuticalsFamilial Cold Autoinflammatory Syndrome

Start: 2021-09-20End: 2023-05-05Updated: 2024-10-09

Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

CompletedNCT04886258

Novartis PharmaceuticalsSymptomatic Knee Osteoarthritis

Start: 2021-09-20End: 2024-12-23Updated: 2026-03-31

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

CompletedNCT06031844

Novartis PharmaceuticalsCoronary Heart Disease

Start: 2023-10-16End: 2024-12-23Updated: 2026-03-27

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

CompletedNCT06097663

Novartis PharmaceuticalsClonal Hematopoiesis of Indeterminate Potential (CHIP), Coronary Heart Disease

Start: 2024-02-15End: 2024-11-04Updated: 2026-03-27

A randomized, placebo-controlled, parallel-group, investigator- and participant-blinded Phase 2a study to investigate the efficacy, safety, and tolerability of DFV890 and MAS825 for inflammatory marker reduction in an adult population with coronary heart disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

CompletedCTIS2023-506741-34-00

Novartis Pharma AGAtherosclerotic cardiovascular disease

Start: 2024-02-16End: 2024-11-04Target: 16Updated: 2024-10-25

A randomized, two-arm, placebo-controlled, participant and investigator-blinded study investigating the efficacy, safety and tolerability of DFV890 in patients with symptomatic knee osteoarthritis

CompletedCTIS2023-507559-30-00

Novartis Pharma AGKnee Osteoarthritis

Start: 2021-11-09End: 2024-12-19Target: 76Updated: 2024-12-16

Related Papers

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood2024-11-055 citations

Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial

Blood Advances2023-11-0736 citations

Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood2023-11-025 citations

DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.

2022-09-1462 citations